Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform.
While no genome-wide pharmacogenetics study has yet been published, the field of pharmacogenetics is moving towards exploratory, large-scale analyses of the interaction between genetic variation and drug treatment. The Drug Metabolizing Enzymes and Transporters (DMET) platform offers a standardized set of 1936 variants in 225 genes related to drug absorption, distribution, metabolism and elimination that is useful to scan the genome for previously unknown associations between variation in absorption, distribution, metabolism and elimination genes and pharmacokinetic and pharmacodynamic outcomes of drug treatment. The purpose of this review is to put the DMET platform into context within the current study designs that have been used in pharmacogenetics, and to explore the role that DMET has played - and will play - in future pharmacogenetics studies.
Sissung
Tristan M
TM
National Cancer Institute, Bethesda, MD 20892, USA.
English
Bevin C
BC
Venzon
David
D
Figg
William D
WD
Deeken
John F
JF
D016208:Databases, Factual; D004798:Enzymes; D005796:Genes; D055106:Genome-Wide Association Study; D006801:Humans; D004364:Pharmaceutical Preparations / Q000378:metabolism; D010597:Pharmacogenetics / Q000379:methods; D010601:Pharmacology, Clinical / Q000379:methods; D057285:Precision Medicine
D004798:Enzymes; D004364:Pharmaceutical Preparations